Appointment of CEO and Managing Director
Perth, Jan 14, 2026 AEST (ABN Newswire) - Proteomics International Laboratories Ltd (
ASX:PIQ) (PIQLF:OTCMKTS) announced the appointment of David Morris as Chief Executive Officer (CEO) and Managing Director (MD).
Mr Morris will assume full operational and strategic responsibilities effective 19 January 2026.
David is a global healthcare and medical technology executive with extensive experience spanning medical devices and life sciences. His career includes executive leadership roles at Cochlear, Nanosonics, Polynovo and Monash IVF, where he has proven track record in commercial growth, international market expansion, successful product commercialisation and building high-performing teams. He brings deep expertise in strategy development, regulatory pathways, global market entry and market development across the Americas, Europe and Asia. His appointment reflects the Company's sharpened focus on commercial execution and global market penetration for the Promarker(R) diagnostic pipeline.
Commenting on his appointment, Mr David Morris said:
"I am excited to be appointed CEO of Proteomics International at such a pivotal stage in the Company's evolution. The Promarker(R) technology platform has the potential to transform disease prediction and management globally. I look forward to working with the Board and the team to deliver on this opportunity for patients and shareholders."
Proteomics International Chair, Dr James Williams, said:
"The Board is delighted to appoint David as CEO. He brings deep commercial expertise in medical technology and a proven ability to translate innovative science into commercial outcomes. With the Company now firmly focused on commercialisation of the Promarker(R) pipeline, David is exceptionally well placed to lead our next phase of growth."
David will succeed Dr Richard Lipscombe, who will retire following 25 years of distinguished leadership as founder and Managing Director. Dr Lipscombe has been instrumental in establishing Proteomics International as a global leader in precision diagnostics. To ensure a seamless transition, Richard will continue to provide support during a handover period until his formal retirement on 23 February 2026.
Dr Williams added: "On behalf of the Board, I would also like to acknowledge and thank Richard for his outstanding contribution in establishing Proteomics International as a recognised leader in precision diagnostics. We are pleased that he will support the leadership transition, and we look forward to his continued support of the Company as a significant shareholder."
About Proteomics International Laboratories Ltd
Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.
| ||
|
X/Twitter
Facebook
LinkedIn
